Entity

Time filter

Source Type


Shurygin A.A.,Perm State Academy Of Medicine Named After Academy Ea Vagner | Lvova I.I.,Perm State Academy Of Medicine Named After Academy Ea Vagner | Deryusheva A.V.,Perm State Academy Of Medicine Named After Academy Ea Vagner | Varankina A.A.,Perm State Academy Of Medicine Named After Academy Ea Vagner | Legotina N.S.,Perm State Academy Of Medicine Named After Academy Ea Vagner
Life Science Journal | Year: 2014

The rationale for immunotherapy with interferon -α-2β (VIFERON® 3 million IU and 1 million IU in suppositories) in the treatment of pulmonary tuberculosis in adolescents was the prevalence of clinical and laboratory markers of secondary immune deficiency identified complex examination 62 hospitalized patients: more than two chronic diseases (75,8%); recurrent infection caused by the herpes simplex viruses (HSV 1,2) (54.8%), on the background of combined serological HSV 1,2activation (90.3%) and cytomegalovirus (CMV) infection (93.6%); the decrease in the absolute number of leukocytes and the low levels orabsence of interferon -alpha (29.0%) and interferon - gamma (77.4%). The efficiency and safety of the treatment with VIFERON® proved on the basis of significant positive clinical and laboratory criteria: an increase in body weight in 84.6% of adolescents; reducing the frequency of arrhythmias; increase in absolute lymphocyte count (46.1%); decreased serological activation HSV 1,2 (30.8%) and CMV (61.5%); increase in the amount of interferon -alpha (61.5%) and interferon - gamma (61.5%);the absence of the intolerance 3 times reduction in the undesirable effects of chemotherapy.

Discover hidden collaborations